TY - JOUR AU - Huang, Yan-xin AU - Zhao, Jian AU - Song, Qiu-hang AU - Zheng, Li-hua AU - Fan, Cong AU - Liu, Ting-ting AU - Bao, Yong-li AU - Sun, Lu-guo AU - Zhang, Li-biao AU - Li, Yu-xin PY - 2016 DA - 2016/07/21 TI - Virtual screening and experimental validation of novel histone deacetylase inhibitors JO - BMC Pharmacology and Toxicology SP - 32 VL - 17 IS - 1 AB - Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases. HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clinical applications. Increasing efforts have been focused on the discovery of HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy. However, most HDAC inhibitors, including the clinically approved agents, do not selectively inhibit the deacetylase activity of class I and II HDAC isforms, and many suffer from metabolic instability. This study aims to identify new HDAC inhibitors by using a high-throughput virtual screening approach. SN - 2050-6511 UR - https://doi.org/10.1186/s40360-016-0075-8 DO - 10.1186/s40360-016-0075-8 ID - Huang2016 ER -